Brief: Oramed Completes Patient Enrollment In Phase 2 Oral Insulin NASH Trial
16/03/2022 12:26
March 16 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL
INSULIN NASH
TRIAL
* ORAMED PHARMACEUTICALS INC - TOPLINE RESULTS FOR PHASE 2
ORAL
INSULIN NASH TRIAL EXPECTED H2 2022
Source text for Eikon: ID:nPn2hFp3Va
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results